QIAGEN's GeneReader NGS System Delivers Accuracy and Ease of Use for Clinical Research in Oncology

HILDEN, Germany and GERMANTOWN, Maryland, November 14, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt Prime Standard: QIA) today announced new studies highlighting the outstanding analytical performance and ease of use of the GeneReader NGS System, the world's first complete Sample to Insight solution for next-generation sequencing. The studies are being presented this week at the Association for Molecular Pathology (AMP) 2017 Annual Meeting in Salt Lake City, Utah, where QIAGEN also will demonstrate the GeneReader and other Sample to Insight solutions.

Click here [https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-14-GeneReader_AMP?sc_lang=en ] for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-14-GeneReader_AMP?sc_lang=en

Contacts: 

QIAGEN 

            Investor Relations                      
        John Gilardi  
        +49-2103-29-11711          
        e-mail: ir@QIAGEN.com  


        Public Relations 
        Dr. Thomas Theuringer 
        +49-2103-29-11826 
        e-mail: pr@QIAGEN.com                            

SOURCE Qiagen N.V.